The CMS' Physician Payment Sunshine Act will make doctors and teaching hospitals' transactions with drug companies and medical technology manufacturers public starting Aug. 1, but some physicians voiced concerns, pointing out that over-interpreting such connections could be detrimental. Advocates of the Sunshine Act say the provision will help prevent conflicts of interest. While the burden of reporting transactions will fall mostly on drug companies and manufacturers, CMS notes it will benefit physicians to keep a record of all transactions with the companies.
Doctors raise concerns over Sunshine Act
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|